"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 1 | 2 |
| 1994 | 0 | 3 | 3 |
| 1995 | 1 | 2 | 3 |
| 1996 | 1 | 3 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 5 | 6 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 2 | 5 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 4 | 7 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 5 | 1 | 6 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 3 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
-
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflamm Bowel Dis. 2022 07 01; 28(7):1012-1018.
-
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
-
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2022 02; 17(1):1-14.
-
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity. J Neurooncol. 2021 May; 152(3):567-572.
-
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. J Rheumatol. 2021 07; 48(7):1073-1081.
-
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020 08; 60(8):1867-1872.
-
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486.